Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)

Raphaèle Séror ,Elke Theander ,S Nishiyama ,Cristina Vollenweider ,Stefano Bombardieri ,Hendrika Bootsma ,Elena Bartoloni ,Pilar Brito-Zerón ,Valérie Devauchelle‐Pensec ,Roser Solans Laqué ,Roberto Caporali ,Petra M Meiners ,É Hachulla ,Kathy L Sivils ,Anne-Laure Fauchais ,Johan G Brun ,Claudio Vitali ,Wan‐Fai Ng ,Aike A Kruize ,Thomas Dörner ,Roberta Priori ,Manuel Ramos-Casals ,Valèria Valim ,Thomas Mandl ,Athanasios G Tzioufas ,Véronique Le Guern ,Alain Saraux ,Vincent Goëb ,Jacques-Éric Gottenberg ,Takayuki Sumida ,Philippe Ravaud ,Gabriel Baron ,Sonja Praprotnik ,Simon Bowman ,Xavier Mariette

doi:10.1136/annrheumdis-2014-206008

Abstract

ObjectivesTo define disease activity levels, minimal clinically important improvement (MCII) and patient-acceptable symptom state (PASS) with the primary Sjögren's syndrome (SS) disease activity indexes: European League Against Rheumatism (EULAR) SS...

Full Text